{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:50:04Z","timestamp":1791989404511,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004434.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000}}],"reference-count":161,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004434.pub6","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T23:06:33Z","timestamp":1616713593000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Endothelin receptor antagonists for pulmonary arterial hypertension"],"prefix":"10.1002","volume":"2021","author":[{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Cardiology; The First Hospital of Hebei Medical University; Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Haematology and Rheumatology; The First Affiliated Hospital of Fujian Medical University; Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Gao","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Deng","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunshen","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD004434.pub6-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD004434.pub6-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0003|cit3","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research Letairis (Ambrisentan) Tablets: Medical Review(s) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022081Orig1s039.pdf"},{"issue":"23","key":"10.1002\/14651858.CD004434.pub6-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0006|cit6","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research Tracleer (Bosentan) Tablets: Medical Review(s) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-290_Tracleer.cfm"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0008|cit8","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research Tracleer (Bosentan) Tablets: Medical Review(s) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-290_Tracleer.cfm"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0011-393X(02)80029-7","article-title":"Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension","volume":"63","author":"Badesch","year":"2002","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"9288","key":"10.1002\/14651858.CD004434.pub6-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"9630","key":"10.1002\/14651858.CD004434.pub6-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub6-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Gali\u00e8","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","article-title":"Evaluation of macitentan in patients with Eisenmenger Syndrome","volume":"139","author":"Gatzoulis","year":"2019","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"70A","DOI":"10.1002\/hep.30256","article-title":"Efficacy and safety of macitentan in patients with portopulmonary hypertension: the randomized, placebo controlled portico trial","volume":"Suppl 1","author":"Krowka","year":"2018","journal-title":"Hepatology. Conference"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub6-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004434.pub6-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0022|cit22","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0023|cit23","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public summary documents by product: Thelin www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0025|cit25","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.ema.europa.eu\/en\/medicines\/human\/EPAR\/thelin"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0026|cit26","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public summary documents by product: Thelin www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0027|cit27","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.ema.europa.eu\/en\/medicines\/human\/EPAR\/thelin"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40256-014-0081-4","article-title":"Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects","volume":"14","author":"Ahn","year":"2014","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics inpatients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub6-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","article-title":"Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects","volume":"52","author":"Atsmon","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.healun.2006.10.019","article-title":"Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan","volume":"26","author":"Benza","year":"2007","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004434.pub6-BIB0034|cit34","first-page":"S276","article-title":"Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser doppler perfusion imaging","volume":"63","author":"Bose","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"3-4","key":"10.1002\/14651858.CD004434.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000367630","article-title":"Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects","volume":"94","author":"Bruderer","year":"2014","journal-title":"Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0036|cit36","unstructured":"Efficacy and safety of oral bosentan in pulmonary fibrosis associated with scleroderma clinicaltrials.gov\/ct2\/show\/NCT00070590"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","article-title":"Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil","volume":"64","author":"Burgess","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s13318-020-00627-3","article-title":"Bioequivalence and tolerability of ambrisentan: a pharmacokinetic study in Mexican healthy male subjects","volume":"45","author":"Cardenas","year":"2020","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0039|cit39","first-page":"A2928","article-title":"Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (PAH): results of the randomized controlled triton study","volume":"201","author":"Chin","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0040|cit40","unstructured":"Coyne TC Garces PC Kramer W No clinical interaction between sitaxsentan and sildenafil American Thoracic Society 2005 International Conference, 2005 May 20-25; San Diego (CA) 2005"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004434.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"ehz747.0004","DOI":"10.1093\/eurheartj\/ehz747.0004","article-title":"Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension","volume":"40","author":"Danaietash","year":"2019","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.jvca.2013.01.023","article-title":"Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial","volume":"27","author":"Denault","year":"2013","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1161\/HYPERTENSIONAHA.111.175646","article-title":"Chronic selective endothelin a receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease","volume":"58","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"204589401984643","DOI":"10.1177\/2045894019846433","article-title":"Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"9","author":"Escribano-Subias","year":"2019","journal-title":"Pulmonary Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.08-2222","article-title":"Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia","volume":"135","author":"Faoro","year":"2009","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0046|cit46","first-page":"333","article-title":"Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension","volume":"30","author":"Fatima","year":"2018","journal-title":"Journal of Ayub Medical College, Abbottabad"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e8","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD004434.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0050|cit50","first-page":"262","article-title":"3-year survival of patients treated with sitaxentan sodium (Thelin) for pulmonary arterial hypertension","volume":"Abstract Supple","author":"Gali\u00e8","year":"2009","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004434.pub6-BIB0051|cit51","first-page":"22, 347","article-title":"Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): results from a phase II study","volume":"3122","author":"Gali\u00e8","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0052|cit52","first-page":"A2513","article-title":"Long term use of imatinib In patients with severe pulmonary arterial hypertension [Abstract]","volume":"181","author":"Ghofrani","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub6-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0054|cit54","first-page":"A5913","article-title":"PAH therapy in HIV: lack of drug-drug interaction between ambrisentan and ritonavir","volume":"183","author":"Gillies","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"25-6","key":"10.1002\/14651858.CD004434.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.lfs.2013.12.227","article-title":"A placebo-controlled study of ambrisentan in subjects with idiopathic pulmonary fibrosis (ARTEMIS-IPF)","volume":"93","author":"Gillies","year":"2013","journal-title":"Life Sciences"},{"issue":"25","key":"10.1002\/14651858.CD004434.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","article-title":"Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure","volume":"101","author":"Givertz","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0057|cit57","unstructured":"Gomberg-Maitland M McLaughlin V Gulati M Rich S Arbor A Efficacy and safety of sildenafil and atorvastatin added to bosentan as therapy for pulmonary arterial hypertension American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego (CA) 2005"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0058|cit58","first-page":"208","article-title":"A randomized open label study comparing first-line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"35","author":"Gotti","year":"2014","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD004434.pub6-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0091270009351173","article-title":"Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers","volume":"50","author":"Gotzkowsky","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0060|cit60","first-page":"692","article-title":"Endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension","volume":"35","author":"Grander","year":"2014","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/bcp.14347","article-title":"Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects","volume":"86","author":"Grill","year":"2020","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5414\/CP201806","article-title":"Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation","volume":"51","author":"Gutierrez","year":"2013","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4187\/respcare.05280","article-title":"Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost","volume":"62","author":"Han","year":"2017","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0064|cit64","first-page":"A14968","article-title":"A double blind, randomized, controlled pharmacokinetic and pharmacodynamics trial of ambrisentan after Fontan surgery","volume":"138","author":"Hill","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Howard LS Ghofrani HA D'Armini AM Fedullo P Gesang S Jais X Long-term safety, tolerability and efficacy of macitentan in patients with inoperable chronic thromboembolic pulmonary hypertension: the merit-1 study and its open-label extension merit-2 American Journal of Respiratory and Critical Care Medicine 2019 A6068","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A6068"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0067|cit67","first-page":"114","article-title":"Role of pulmonary hypertension and right ventricular dysfunction in aerobic exercise capacity limitation in normal volunteers at high altitude","volume":"64","author":"Huez","year":"2009","journal-title":"Acta Cardiologica"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jcph.639","article-title":"Lack of pharmacokinetic interactions between macitentan and a combined oral contraceptive in healthy female subjects","volume":"56","author":"Hurst","year":"2016","journal-title":"American College of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD004434.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"European Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD004434.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"2-3","key":"10.1002\/14651858.CD004434.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-9-69","article-title":"A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy","volume":"9","author":"Kefford","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0074|cit74","first-page":"1179","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia: a randomized, double-blind, placebo-controlled study","volume":"42","author":"Keir","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD004434.pub6-BIB0075|cit75","first-page":"P2335","article-title":"Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia [Abstract]","volume":"44","author":"Keir","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"Behr","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8977","key":"10.1002\/14651858.CD004434.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart, Lung and Circulation"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1042\/CS20080241","article-title":"Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"116","author":"Lee","year":"2009","journal-title":"Clinical Science"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pupt.2014.04.007","article-title":"Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects","volume":"29","author":"Lindegger","year":"2014","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0082|cit82","first-page":"A3535","article-title":"A randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): long-term results","volume":"187","author":"Mazzanti","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub6-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"18","key":"10.1002\/14651858.CD004434.pub6-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD004434.pub6-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"919A","DOI":"10.1378\/chest.1114871","article-title":"The effect of the ET-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17 week, double-blind, placebo-controlled crossover pilot study","volume":"140","author":"Metersky","year":"2011","journal-title":"Chest"},{"issue":"13","key":"10.1002\/14651858.CD004434.pub6-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/CIRCULATIONAHA.105.605527","article-title":"Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study","volume":"114","author":"Modesti","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1183\/09031936.00024410","article-title":"Pulmonary artery pressure limits exercise capacity at high altitude","volume":"36","author":"Naeije","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0090|cit90","first-page":"301","article-title":"Pharmacokinetics of ambrisentan, a novel drug for treatment of Pulmonary Arterial Hypertension (PAH), in Japanese subjects","volume":"41","author":"Nakahara","year":"2010","journal-title":"Japanese Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0091|cit91","unstructured":"Efficacy and safety of oral bosentan on healing\/prevention of digital (finger) ulcers in patients with scleroderma patients (RAPIDS-2) clinicaltrials.gov\/ct2\/show\/NCT00077584"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.clinthera.2019.04.007","article-title":"A phase I study to show the relative bioavailability and bioequivalence of fixed-dose combinations of ambrisentan and tadalafil in healthy subjects","volume":"41","author":"Okour","year":"2019","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0093|cit93","first-page":"474a","article-title":"Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension","volume":"132","author":"Oudiz","year":"2007","journal-title":"Chest"},{"issue":"21","key":"10.1002\/14651858.CD004434.pub6-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004434.pub6-BIB0095|cit95","first-page":"A3357","article-title":"A randomized open label study comparing bosentan to sildenafil first-line treatment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [Abstract]","volume":"181","author":"Palazzini","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004434.pub6-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"Raghu","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jtcvs.2009.03.053","article-title":"Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension","volume":"139","author":"Reesink","year":"2010","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1183\/09031936.06.00095705","article-title":"A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension","volume":"27","author":"Robbins","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.bjp.0701923","article-title":"Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects","volume":"124","author":"Schmetterer","year":"1998","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/niox.2001.0357","article-title":"The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin A receptor antagonist in men","volume":"5","author":"Schmidt","year":"2001","journal-title":"Nitric Oxide"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/eurjhf\/hft017","article-title":"Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial","volume":"15","author":"Schuuring","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"2-3","key":"10.1002\/14651858.CD004434.pub6-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.resp.2008.10.005","article-title":"Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude","volume":"165","author":"Seheult","year":"2009","journal-title":"Respiratory Physiology and Neurobiology"},{"issue":"7","key":"10.1002\/14651858.CD004434.pub6-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/art.22634","article-title":"Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis","volume":"56","author":"Sfikakis","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0106|cit106","first-page":"1025","article-title":"Efficacy of endothelin receptor antagonist bosentan on the long-term prognosis in patients after Fontan operation","volume":"41","author":"Shang","year":"2013","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11596-016-1621-8","article-title":"Efficacy of bosentan in patients after fontan procedures: a double-blind, randomized controlled trial","volume":"36","author":"Shang","year":"2016","journal-title":"Journal of Huazhong University of Science and Technology [Medical Sciences]"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0108|cit108","first-page":"A1892","article-title":"Comparison of efficacy of different treatment regimens in pulmonary hypertension secondary to lung disease and\/or hypoxia [Abstract]","volume":"189","author":"Sharma","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/ijr.11.8","article-title":"Tadalafil: a new role in Raynaud's phenomenon?","volume":"6","author":"Shenoy","year":"2011","journal-title":"International Journal of Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0110|cit110","first-page":"930","article-title":"Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects","volume":"70","author":"Sidharta","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub6-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.152","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects","volume":"53","author":"Sidharta","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004434.pub6-BIB0112|cit112","first-page":"S108","article-title":"Macitentan, a novel dual endothelin receptor antagonist, does not prolong the QT\/QTC interval in a thorough QTC study in healthy subjects","volume":"93","author":"Sidharta","year":"2013","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub6-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40261-014-0207-0","article-title":"Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects","volume":"34","author":"Sidharta","year":"2014","journal-title":"Clinical Drug Investigation"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004434.pub6-BIB0114|cit114","first-page":"A2515","article-title":"Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH)","volume":"181","author":"Simonneau","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD004434.pub6-BIB0115|cit115","first-page":"OA1984","article-title":"Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study","volume":"50","author":"Simonneau","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/0091270008324180","article-title":"Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers","volume":"48","author":"Spence","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub6-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.2009.03541.x","article-title":"The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects","volume":"69","author":"Stavros","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub6-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/clc.22197","article-title":"Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension","volume":"36","author":"Surie","year":"2013","journal-title":"Clinical Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12890-017-0523-2","article-title":"Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis - an interim analysis of results from a prospective, single-center, randomized, parallel-group study","volume":"17","author":"Tanaka","year":"2017","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0122|cit122","doi-asserted-by":"crossref","unstructured":"Tanaka Y Hino M Aoyama J Kosaihira S Okano T Seike M Interim report: long-term influence of bosentan on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with pulmonary hypertension secondary to COPD Respirology 2019 239","DOI":"10.1111\/resp.13700_453"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0123|cit123","first-page":"1880","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Delcroix","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ki.5000215","article-title":"Selective endothelin B receptor blockade does not influence BNP-induced natriuresis in man","volume":"69","author":"Van Der Zander","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0091270004270833","article-title":"Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects","volume":"45","author":"Van Giersbergen","year":"2005","journal-title":"American College of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40268-017-0201-0","article-title":"Longitudinal assessment of the effect of atrasentan on thoracic bioimpedance in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Webb","year":"2017","journal-title":"Drugs in R&D"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0127|cit127","first-page":"1","article-title":"Safety and feasibility of inhaled iloprost on exercise capacity in patients with pulmonary arterial hypertension","volume":"19","author":"Worthington","year":"2010","journal-title":"Heart Lung and Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004434.pub6-BIB0129|cit129","first-page":"1531","article-title":"AB0797\u2005A randomised double blind placebo controlled trial to compare the efficacy of initial combination therapy vs monotherapy for pulmonary arterial hypertension in systemic sclerosis","volume":"77","author":"Dwivedi","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Rinaldi A Dardi F Albini A Gotti E Monti E Palazzini M Haemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension European Heart Journal 2018 P6341","DOI":"10.1093\/eurheartj\/ehy566.P6341"},{"issue":"7382","key":"10.1002\/14651858.CD004434.pub6-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Statistics notes: interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1378\/chest.132.4_MeetingAbstracts.488b","article-title":"Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology","volume":"132","author":"Badesch","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5339\/gcsp.2014.29","article-title":"The role of endothelin-1 in pulmonary arterial hypertension","volume":"2014","author":"Chester","year":"2014","journal-title":"Global Cardiology Science and Practice"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0135|cit135","unstructured":"Veritas Health InnovationCovidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub6-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2016.12.092","article-title":"Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: a network meta-analysis","volume":"234","author":"Duo-Ji","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0139|cit139","unstructured":"McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 20 Novmber 2020. Hamilton (ON): McMaster University (developed by Evidence Prime)"},{"issue":"130","key":"10.1002\/14651858.CD004434.pub6-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1183\/09059180.00007513","article-title":"Pathogenesis of pulmonary arterial hypertension: lessons from cancer","volume":"22","author":"Guignabert","year":"2013","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1254\/jphs.13R02CR","article-title":"Endothelin receptor signaling: new insight into its regulatory mechanisms","volume":"123","author":"Horinouchi","year":"2013","journal-title":"Journal of Pharmacological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1513\/AnnalsATS.201512-824OC","article-title":"The minimal important difference in Borg dyspnea score in pulmonary arterial hypertension","volume":"13","author":"Khair","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and Expert Panel Report","volume":"155","author":"Klinger","year":"2019","journal-title":"CHEST"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10557-015-6605-6","article-title":"Pathways and drugs in pulmonary arterial hypertension - focus on the role of endothelin receptor antagonists","volume":"29","author":"Madonna","year":"2015","journal-title":"Cardiovascular Drugs Therapy"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub6-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0148|cit148","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0150|cit150","doi-asserted-by":"crossref","unstructured":"Seibold J Badesch D Gali\u00e8 N Langleben D Naeije R Simonneau G Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD) CHEST 2005 128 4 219S","DOI":"10.1378\/chest.128.4_MeetingAbstracts.219S"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.phrs.2011.03.003","article-title":"The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension","volume":"63","author":"Shao","year":"2011","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub6-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub6-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1080\/10717544.2018.1523257","article-title":"A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension","volume":"25","author":"Wang","year":"2018","journal-title":"Drug Delivery"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub6-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertension Research"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub6-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub2","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub3","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub6-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub4","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub6-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub5","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:53:14Z","timestamp":1698108794000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004434.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":161,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004434.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}